Zoom In on Dementia & Alzheimer's Episodes
Learn about the Bio-Hermes-002 study exploring blood and digital biomarkers for predicting Alzheimer’s pathology. Discover accessible detection methods and treatment eligibility.
Join us to learn the basics of what blood biomarkers are, how they work, and why they’re considered a game-changer in Alzheimer’s research and clinical care.
Advancements in diagnostic technologies such as blood tests and AI-based models is making early detection of dementia quicker, less expensive, more accurate and more accessible than ever before. Join Dr. David M. Holtzman, a leading neurologist and Alzheimer’s expert as he shares insights on the latest diagnostic methods, when and how to seek a diagnosis, and how to navigate the process.
The Synaptic Therapy Alzheimer’s Research Trial (START) study, currently enrolling participants at sites across the U.S., is evaluating a new oral capsule designed to slow memory loss in Alzheimer’s by safeguarding synapses in the brain. Listen to lead research scientist Dr. Christopher van Dyck to learn more.
Learn about participating in clinical trials for frontotemporal dementia with Dr. Brad Dickerson.
Join Cognito Therapeutics CEO, Brent Vaughan to talk about the pivotal HOPE Study, an investigational medical device consisting of headphones and eyewear to deliver sensory stimulation treatment in the comfort of people’s homes.
On July 2, 2024, the U.S. Food and Drug Administration approved Kisunla (donanemab), a new Alzheimer’s medication shown to slow the progression of the disease. Join our conversation with Dr. Paul Aisen as he details how the drug works, for whom, side effects, what it costs, whether it’s covered by insurance, and how it compares with other new Alzheimer’s medicines.
If you learn about your specific genetic makeup early enough – before symptoms of memory loss begin – could you benefit from this knowledge? Would you be eligible for specific types of treatment? Join us as we explore the importance of understanding your genetic risk for Alzheimer’s and related dementias.
Are you between 18-95 years old and interested in brain health? Learn from leading scientists about two research opportunities that do NOT involve taking medications: the Emory Healthy Aging Study and the NeuroQuest Study.
This year, the Food and Drug Administration approved an artificial intelligence (AI) tool called BrainSee to predict the likelihood of Alzheimer’s progression using brain scans. Are AI programs the next frontier in forecasting, understanding, and managing Alzheimer’s? Dr. Timothy Hohman gives us the scoop on all things AI and dementia.
